Pfe 2022

Pharmaceutical Investing

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Markets
TSX	19990.17	-252.09
TSXV	581.25	-0.39
DOW	33596.34	-350.76
S&P 500	3941.26	-57.58
NASD	11014.89	-225.05
ASX	7325.60	+24.10

Markets

TSX

19990.17

-252.09

TSXV

581.25

-0.39

DOW

33596.34

-350.76

S&P 500

3941.26

-57.58

NASD

11014.89

-225.05

ASX

7325.60

+24.10

Commodities
Gold	1770.39	-0.59
Silver	22.16	-0.01
Copper	3.82	0.00
Palladium	1858.68	+11.69
Platinum	992.50	+3.50
Oil	74.61	+0.36
Heating Oil	2.92	+0.01
Natural Gas	5.45	-0.02

Commodities

Gold

1770.39

-0.59

Silver

22.16

-0.01

Copper

3.82

0.00

Palladium

1858.68

+11.69

Platinum

992.50

+3.50

Oil

74.61

+0.36

Heating Oil

2.92

+0.01

Natural Gas

5.45

-0.02

TomaGold closes $974,125 first tranche of private placement and grants options

Investing News NetworkYour trusted source for investing success

Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease

Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus Vaccine Candidate

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination

Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

MARKETS

COMMODITIES

DOWNLOAD FREE REPORTS

Updated! Download Your FREE 2022 Energy Outlook Report.

NEW! Download Your 2022 Oil & Gas Outlook Report.

NEW! Download Your 2022 Industrial Metals Outlook Report.

Free! Download Your FREE 2022 Base Metals Outlook Report [Updated Nov 3]

NEW! Download Your FREE 2022 Diamond Outlook Report

NEW! Download Our FREE 2022 Gaming Outlook Report. [Updated Aug 12]

FREE 2022 Blockchain Investor Report [Updated Aug 5]

Gold vs Bitcoin – Dogfight or Detente?

Start Here – Investing in Cleantech

Biotech Investing: Top Biotech ETFS, Stocks, Future Prospects

NEW! Download Your FREE 2022 Pharmaceuticals Outlook Report.

FREE 2022 Psychedelics Investor Report [Updated Aug 5]

Start Here – Investing in Pharma

Start Here – Investing in Genetics

BROWSE COMPANIES BY SECTOR

Featured Stocks

Valore Metals

Blue Star Helium

Bold Ventures

Slave Lake Zinc

Ultra Lithium

Redstone Resources